Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA

Guardado en:

Detalles Bibliográficos
Autores principales:	Sam Gandy, David S. Knopman, Mary Sano
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Aduhelm® (aducanumab) Amyloid beta Donanemab Lecanemab Gantenerumab Neurology. Diseases of the nervous system RC346-429 Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/f92c16d8aa1a4a8380db476dc21f17d2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f92c16d8aa1a4a8380db476dc21f17d2
record_format	dspace
spelling	oai:doaj.org-article:f92c16d8aa1a4a8380db476dc21f17d22021-11-08T10:45:21ZTalking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA10.1186/s13024-021-00490-z1750-1326https://doaj.org/article/f92c16d8aa1a4a8380db476dc21f17d22021-11-01T00:00:00Zhttps://doi.org/10.1186/s13024-021-00490-zhttps://doaj.org/toc/1750-1326Sam GandyDavid S. KnopmanMary SanoBMCarticleAduhelm® (aducanumab)Amyloid betaDonanemabLecanemabGantenerumabNeurology. Diseases of the nervous systemRC346-429GeriatricsRC952-954.6ENMolecular Neurodegeneration, Vol 16, Iss 1, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aduhelm® (aducanumab) Amyloid beta Donanemab Lecanemab Gantenerumab Neurology. Diseases of the nervous system RC346-429 Geriatrics RC952-954.6
spellingShingle	Aduhelm® (aducanumab) Amyloid beta Donanemab Lecanemab Gantenerumab Neurology. Diseases of the nervous system RC346-429 Geriatrics RC952-954.6 Sam Gandy David S. Knopman Mary Sano Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
format	article
author	Sam Gandy David S. Knopman Mary Sano
author_facet	Sam Gandy David S. Knopman Mary Sano
author_sort	Sam Gandy
title	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
title_short	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
title_full	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
title_fullStr	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
title_full_unstemmed	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
title_sort	talking points for physicians, patients and caregivers considering aduhelm® infusion and the accelerated pathway for its approval by the fda
publisher	BMC
publishDate	2021
url	https://doaj.org/article/f92c16d8aa1a4a8380db476dc21f17d2
work_keys_str_mv	AT samgandy talkingpointsforphysicianspatientsandcaregiversconsideringaduhelminfusionandtheacceleratedpathwayforitsapprovalbythefda AT davidsknopman talkingpointsforphysicianspatientsandcaregiversconsideringaduhelminfusionandtheacceleratedpathwayforitsapprovalbythefda AT marysano talkingpointsforphysicianspatientsandcaregiversconsideringaduhelminfusionandtheacceleratedpathwayforitsapprovalbythefda
_version_	1718442675023118336

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA

Ejemplares similares